» Articles » PMID: 37959263

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Nov 14
PMID 37959263
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and particularly, the pooled analysis of both studies, have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total HF hospitalizations, and MACE in the whole spectrum of HF, with sustained benefits over time. Recent data have shown that the full implementation of dapagliflozin in clinical practice would translate into a robust reduction in hospitalizations for HF and death in real-life populations. Many pathophysiological mechanisms have been involved in these benefits, particularly the positive effects of dapagliflozin on reversing cardiac (atrial and ventricular) remodeling, reducing cardiac fibrosis and inflammation, and improving endothelial dysfunction. In this manuscript, we reviewed from a practical point of view the role of dapagliflozin in the management of the whole spectrum of patients with HF.

Citing Articles

Underlying mechanisms of ketotherapy in heart failure: current evidence for clinical implementations.

Liu K, Yang Y, Yang J Front Pharmacol. 2024; 15:1463381.

PMID: 39512825 PMC: 11540999. DOI: 10.3389/fphar.2024.1463381.


Oxidative stress and senescence in aging kidneys: the protective role of SIRT1.

Almalki W, Salman Almujri S EXCLI J. 2024; 23:1030-1067.

PMID: 39391060 PMC: 11464868. DOI: 10.17179/excli2024-7519.


Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling.

Minciuna I, Tomoaia R, Mihaila D, Cismaru G, Puiu M, Rosu R Curr Issues Mol Biol. 2024; 46(9):9607-9623.

PMID: 39329923 PMC: 11430639. DOI: 10.3390/cimb46090571.


Editorial for the Special Issue on Sglt2 Inhibitors (Volume 2).

Lymperopoulos A Int J Mol Sci. 2023; 24(23).

PMID: 38069186 PMC: 10706270. DOI: 10.3390/ijms242316865.

References
1.
Chioncel O, Mebazaa A, Maggioni A, Harjola V, Rosano G, Laroche C . Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019; 21(11):1338-1352. DOI: 10.1002/ejhf.1492. View

2.
Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

3.
Obaya J, Escobar C, Pallares V, Egocheaga I . [Practical approach of dapagliflozin for the treatment of heart failure. Role of primary care physician]. Semergen. 2021; 47 Suppl 1:5-10. DOI: 10.1016/j.semerg.2021.08.003. View

4.
Nassif M, Windsor S, Gosch K, Borlaug B, Husain M, Inzucchi S . Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. Circ Heart Fail. 2023; 16(7):e009837. PMC: 10348645. DOI: 10.1161/CIRCHEARTFAILURE.122.009837. View

5.
Curtain J, Docherty K, Jhund P, Petrie M, Inzucchi S, Kober L . Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021; 42(36):3727-3738. PMC: 8455345. DOI: 10.1093/eurheartj/ehab560. View